CDTTW
CDT Equity Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.01
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.4B | — | — | — | — |
| Cost of Revenue | 887.4M | — | — | — | — |
| Gross Profit | 559.1M | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 65.3M | 5.1M | 3.4M | 90.0K | 111.0K |
| SG&A Expense | 315.3M | 31.7M | 12.0M | 5.2M | 3.0M |
| General & Admin Expense | 164.6M | 31.7M | 12.0M | 5.2M | 3.0M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 11.4M | — | — | — | — |
| Total Operating Expenses | 392.0M | 36.8M | 15.4M | 5.3M | 3.2M |
| Cost and Expenses | 1.3B | 36.8M | 15.4M | 5.3M | 3.2M |
| Operating Income (EBIT) | 167.1M | (36.8M) | (15.4M) | (5.3M) | (3.2M) |
| Non-Operating | |||||
| Interest Income | 16.0K | 28.0K | 13.0K | 15.0K | 2.0M |
| Interest Expense | (27.0M) | 319.0K | 1.5M | 211.0K | — |
| Net Interest Income | 27.0M | (291.0K) | (1.5M) | (196.0K) | 2.0M |
| Other Non-Op Income/Expense | (47.6M) | (2.5M) | (2.4M) | 8.1M | (1.7M) |
| Non-Operating Income (excl Interest) | (7.9M) | 2.1M | 877.0K | (8.3M) | 1.7M |
| EBT (Pre-Tax Income) | 119.5M | (39.2M) | (17.8M) | 2.8M | (4.9M) |
| Income Tax Expense | 28.4M | — | — | — | — |
| Bottom Line | |||||
| Net Income | 91.1M | (39.2M) | (17.8M) | (535.0K) | (4.9M) |
| Earnings from Cont. Ops | 91.1M | (39.2M) | (17.8M) | 2.8M | (4.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 91.1M | (39.2M) | (17.8M) | (6.1M) | (4.9M) |
| Per Share | |||||
| Basic EPS | $76.72 | ($117.79) | ($6,159.30) | ($239.70) | ($2,013.60) |
| Diluted EPS | $75.70 | ($117.79) | ($6,159.30) | ($2,676.00) | ($2,013.60) |
| Revenue Per Share | $37.20 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 38.9M | 333000 | 2890 | 2232 | 2427 |
| Diluted Shares Outstanding | 39.3M | 333000 | 2890 | 2263 | 2427 |
| Profitability Metrics | |||||
| EBITDA | 243.3M | (36.5M) | (15.8M) | 3.1M | (4.9M) |
| D&A | 68.2M | 2.4M | 457.0K | — | — |
| EBIT | 175.1M | (38.9M) | (16.3M) | 3.1M | (4.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026